Schizophrenia and psychoneuroimmunology: An integrative view

Current Opinion in Psychiatry

Volumn 28, Issue 3, 2015, Pages 201-206

  Sperner Unterweger, Barbara ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

immune response; neurotransmitter pathways; psychoneuroimmunology; schizophrenia

Indexed keywords

ANTIBODY; CYTOKINE; NEUROTRANSMITTER; 5,6,7,8-TETRAHYDROPTERIDINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PHENYLALANINE 4 MONOOXYGENASE; PTERIDINE DERIVATIVE;

DNA POLYMORPHISM; ENZYME ACTIVITY; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE RESPONSE; MENTAL PATIENT; NEUROTRANSMISSION; OXIDATIVE STRESS; PSYCHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SEROPREVALENCE; AUTOIMMUNITY; BRAIN; IMMUNOLOGY; INFLAMMATION; METABOLISM;

AUTOIMMUNITY; BRAIN; CYTOKINES; HUMANS; INFLAMMATION; NEUROTRANSMITTER AGENTS; PHENYLALANINE HYDROXYLASE; PSYCHONEUROIMMUNOLOGY; PTERIDINES; SCHIZOPHRENIA;

EID: 84926335211     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000153     Document Type: Review

References (59)

1. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014; 75: 324-331.
2. Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry 2014; 75: 300-306.
3. Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168: 1303-1310.
4. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013; 45: 1150-1159.
5. Andreassen OA, Harbo HF, Wang Y, et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry 2015; 20: 207-214.
6. Monji A, Kato TA, Mizoguchi Y, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 115-121.
7. Zavitsanou K, Lim CK, Purves-Tyson T, et al. Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induces hyperlocomation in adulthood: amelioration by COX-2 inhibition. Brain Behav Immun 2014; 41: 173-181.
8. Okusaga O, Muravitskaja O, Fuchs D, et al. Elevated levels of plasma phenylalanine in schizophrenia: a guanosine triphosphate cyclohydrolase-1 metabolic pathway abnormality? PLoS One 2014; 9: e85945.
9. Hwang Y, Kim J, Shin JY, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013; 3: e321. doi: 10.1038/tp.2013.94.
10. Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol Psychiatry 2013; 75: 276-283.
11. Sinkus ML, Adams CE, Logel J, et al. Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. Brain Behav Immun 2013; 32: 51-62.
12. Ohi K, Hashimoto R, Ikeda M, et al. Glutamate networks implicate cognitive impairments in schizophrenia: Genome-wide association studies of 52 cognitive phenotypes. Schizophr Bull 2014; doi: 10.1093/schbul/sbu171. [Epub ahead of print]
13. Zakharyan R, Boyajyan A. Brain-derived neurotrophic factor blood levels are decreased in schizophrenia patients and associate with rs6265 genotypes. Clin Biochem 2014; 47: 1052-1055.
14. Lin Z, Su Y, Zhang C, et al. The interaction of BDNF and NTRK2 gene increases the susceptibility of paranoid schizophrenia. PLoS One 2013; 8: e74264.
15. Frydecka D, Misiak B, Beszlej JA, et al. Genetic variants in transforming growth factor-beta gene (TGFB1) affect susceptibility to schizophrenia. Mol Biol Rep 2013; 40: 5607-5614.
16. Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci 2014; DOI 10.1007/s00406-014-0533-5. [Epub ahead of print]
17. Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 2014; 71: 255-264.
18. Auta J, Smith RC, Dong E, et al. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr Res 2013; 150: 312-318.
19. Durrenberger PF, Fernando FS, Kashefi SN, et al. Common mechanisms in neurodegeneration and neuroinflammation: A BrainNet Europe gene expression microarray study. J Neural Transm 2014; DOI 10.1007/s00702-14-1293-0. [Epub ahead of print]
20. Blomström A, Karlsson H, Svensson A, et al. Hospital admission with infection during childhood and risk for psychotic illness-a population-based cohort study. Schizophr Bull 2014; 40: 1518-1525.
21. Kalmady SV, Venkatasubramanian G, Shivakumar V, et al. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: evidence for differential susceptibility? PLoS One 2014; 9: e96021. doi: 10.1371/journal.pon.
22. Venkatasubramanian G, Debnath M. Neuroimmunological aberrations and cerebral asymmetry abnormalieits in schizophrenia: select perspectives on pathogenesis. Clin Psychopharmacol Neurosci 2014; 12: 8-18.
23. Burt MA, Tse YC, Boksa P, et al. Prenatal immune activation interacts with stress and corticosterone exposure later in life to modulate N-methyl-Daspartate receptor synaptic function and plasticity. Int J Neuropsychopharmacol 2013; 16: 1835-1848.
24. Bronson SL, Bale TL. Prenatal Stress-induced increases in placental inflammation and offspring hyperactivity are male-specific and ameliorated by maternal anti-inflammatory treatment. Endocrinology 2014; 155: 2635-2646.
25. Richetto J, Calabese F, Riva MA, Meyer U. Prenatal immune activation induces maturation-dependet alterations in the prefrontal GABAergic transcriptome. Schizophr Bull 2014; 40: 351-361.
26. Nielsen PR, Agerbo E, Skogstrans K, et al. Neonatal levels of inflammatory markers and later risk of schizophrenia. Biol Psychiatry 2015; 77: 548-555.
27. Børglum AD, Demontis D, Grove J, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Mol Psychiatry 2014; 19: 325-333.
28. Hannachi N, Kissi YE, Samoud S, et al. High prevalence of human herpevirus 8 in schizophrenic patients. Psychiatry Res 2014; 216: 192-197.
29. Li Y, Weber NS, Fisher JA, et al. Association between antibodies to multiple infectious and food antigens and new onset schizophrenia among US military personnel. Schizophr Res 2013; 151: 36-42.
30. Severance EG, Gressitt KL, Alaedini A, et al. IgG dynamics of dietary antigens point to cerebrospinal fluid barrier of flow dysfunction in first-episode schizophrenia. Brain Behav Immun 2014; 44: 148-158.
31. Monroe JM, Buckley PF, Miller BJ. Meta-analysis of antitoxoplasma gondii IgM antibodies in acute psychosis. Schizophr Bull 2014; doi: 10.1093/schbul/ sbu159. [Epub ahead of print]
32. Okusaga O, Langenberg P, Sleemi A, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia. Schizophr Res 2011; 133: 150-155.
33. Benros ME, Pedersen MG, Rasmussen H, et al. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry 2014; 171: 218-226.
34. Stringer S, Kahn RS, de Witte LD, et al. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr Res 2014; 159: 347-352.
35. Pathmanandavel K, Starling J, Merheb V, et al. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children. Biol Psychiatry 2015; 77: 537-547.
36. Steiner J, Teegen B, Schiltz K, et al. Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry 2014; 71: 838-839.
37. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014; 76: 82-94.
38. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 2014; 155: 101-108.
39. Nielsen J, Roge R, Pristed SG, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. Schizophr Bull 2014; doi: 10.1093/schbul/sbu118. [Epub ahead of print]
40. Miller BJ, Kandhal P, Rapaport MH, Mellor A, et al. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in nonaffective psychoses. Brain Behav Immun 2015; pii: S0889-1591(14)00568-6. doi: 10.1016/j.bbi.2014.12.005. [Epub ahead of print]
41. Tourjman V, Kouassi E, Koue ME, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a metaanalysis. Schizophr Res 2013; 151: 43-47.
42. Ajami A, Hosseini SH, Taghipour M, Khalilian A.Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment. Scan J Immunol 2014; 80: 36-42.
43. Noto C, Ota VK, Gouveia ES, et al. Effects of risperidone on cytokine profile in drug naïve first episode psychosis. Int J Neuropsychopharmacol 2015; 31: pii: pyu042. [Epub ahead of print].
44. De Witte L, Tomasik J, Schwarz E, et al. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 2014; 154: 23-29.
45. Xiu MH, Yang GG, Tan YL, et al. Decreased interleukin-10 serum levels in firstepisode drug-naïve schizophrenia: relationship to psychopathology. Schizophr Res 2014; 156: 9-14.
46. Dimitrov DH, Lee S, Yantis J, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL17 pathway. Schizophr Res 2013; 151: 29-35.
47. Ding M, Song X, Zhao J, et al. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 51: 78-82.
48. Miller BJ, Gassama B, Sebastian D, et al. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2013; 73: 993-999.
49. Asevedo E, Rizzo LB, Gadelha A, et al. Peripheral interleukin-2 level is associated with negative symptoms and conitive performance in schizophrenia. Physiology Behavior 2014; 129: 194-198.
50. Schwarz E, van Beveren NJM, Ramsey J, et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr Bull 2014; 40: 787-795.
51. Ma-xeiner HG, Schneider ME, Kurfiss ST, et al. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine 2014; 69: 62-67.
52. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
53. Fillman SG, Sinclair D, Fung SJ, et al. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365. doi: 10.1038/tp.2014.8.
54. Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013; 47: 401-406.
55. Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 2014; 39: 140126. doi: 10.1503/jpn.140126.
56. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynureine pathway in schizophrenia. Int J Tryptophan Res 2014; 7: 15-22.
57. Gos T, Myint AM, Schiltz K, et al. Reduces microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav Immun 2014; 41: 59-64.
58. Sperner-Unterweger B, Barnas C, Fleischhacker WW, et al. Is schizophrenia linked to alteration in cellular immunity? Schizophr Res 1989; 2: 417-421.
59. Bechter K, Reiber H, Herzog S, et al. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010; 44: 321-330.